Table 3.
Clinical and laboratory features according to NLR and PLR at diagnosis
| Variables | NLR <3.2, n=83 | NLR ≥3.2, n=70 | P-value | PLR <122.7, n=57 | PLR ≥122.7, n=96 | P-value |
|---|---|---|---|---|---|---|
| Age (range), years (n=153) | 61 (28–75) | 62 (35–79) | 0.321 | 61 (28–78) | 62 (35–79) | 0.621 |
| Sex (n=153) | 0.121 | 0.465 | ||||
| Male | 60 (72.3) | 58 (82.9) | 45 (78.9) | 73 (76.0) | ||
| Female | 23 (27.7) | 12 (17.1) | 12 (21.1) | 26 (24.0) | ||
| Smoking status (n=153) | 0.218 | 0.853 | ||||
| Never smoker | 29 (34.9) | 18 (25.7) | 17 (29.8) | 30 (31.3) | ||
| Current or ex-smoker | 54 (65.1) | 52 (74.3) | 40 (70.2) | 66 (68.7) | ||
| Stage (n=153) | <0.01 | 0.009 | ||||
| LS | 58 (69.9) | 27 (38.6) | 43 (75.4) | 52 (54.2) | ||
| ES | 25 (30.1) | 43 (61.4) | 14 (24.6) | 44 (45.8) | ||
| KPS at diagnosis (n=153) | 0.043 | 0.481 | ||||
| ≥80 | 79 (95.2) | 60 (85.7) | 53 (93.0) | 86 (89.6) | ||
| <80 | 4 (4.8) | 10 (14.3) | 4 (7.0) | 10 (10.4) | ||
| Hb at diagnosis (n=153) | 1.000 | 0.212 | ||||
| Normal (≤ULN) | 79 (95.2) | 67 (95.7) | 55 (97.4) | 87 (90.6) | ||
| Low (<LLN) | 4 (4.8) | 3 (4.3) | 2 (2.6) | 9 (9.4) | ||
| Alb at diagnosis (n=136) | 0.005 | 0.132 | ||||
| Normal (≤ULN) | 65 (83.3) | 36 (62.1) | 42 (80.8) | 58 (69.0) | ||
| Low (<LLN) | 13 (16.7) | 22 (37.9) | 10 (19.2) | 26 (31.0) | ||
| LDH at diagnosis (n=136) | 0.373 | 0.647 | ||||
| Normal (<ULN) | 45 (57.7) | 29 (50.0) | 27 (51.9) | 47 (55.9) | ||
| High (≥ULN) | 33 (42.3) | 29 (50.0) | 25 (48.1) | 37 (44.1) | ||
| ALP at diagnosis (n=136) | 0.069 | 0.088 | ||||
| Normal (<ULN) | 75 (96.2) | 51 (87.9) | 51 (98.1) | 75 (89.3) | ||
| High (≥ULN) | 39 (3.8) | 7 (12.1) | 1 (11.9) | 9 (10.7) | ||
| PLR at diagnosis, mean ± sd (n=153) | 127.08±41.07 | 180.47±66.04 | <0.01 | |||
| NLR at diagnosis, mean ± sd (n=153) | 2.64±0.99 | 3.62±1.43 | <0.01 | |||
| Response for initial chemotherapy (n=153) | 0.027 | 0.041 | ||||
| CR | 5 (6.0) | 4 (5.7) | 2 (3.5) | 2 (2.1) | ||
| PR | 73 (88.0) | 50 (71.4) | 51 (89.5) | 73 (76.0) | ||
| SD | 3 (3.6) | 10 (14.3) | 1 (1.8) | 16 (16.7) | ||
| PD | 2 (2.4) | 6 (8.6) | 3 (5.3) | 5 (5.2) | ||
| Prophylactic cranial irradiation (n=127) | 0.004 | 0.541 | ||||
| Yes | 23 (33.8) | 7 (11.9) | 13 (26.5) | 17 (21.8) | ||
| No | 45 (66.2) | 52 (88.1) | 36 (73.5) | 61 (78.2) | ||
| Inflammation at diagnosis (n=153) | 0.326 | 0.476 | ||||
| Yes | 18 (21.7) | 20 (28.6) | 16 (28.1) | 22 (22.9) | ||
| No | 65 (78.3) | 50 (71.4) | 41 (71.9) | 74 (77.1) | ||
| Stimulate neutrophil medicine (n=153) | 0.346 | 0.705 | ||||
| Yes | 68 (81.9) | 53 (75.7) | 46 (80.7) | 75 (78.1) | ||
| No | 15 (18.1) | 17 (24.3) | 11 (19.3) | 21 (21.9) | ||
| RT dose, mean ± sd (n=153) | 53.98±5.87 | 51.87±6.99 | 0.047 | 54.11±6.05 | 52.36±6.65 | 0.127 |
| Radiation modes (n=153) | 0.502 | 0.503 | ||||
| CFR | 72 (86.7) | 58 (82.9) | 47 (82.5) | 83 (86.5) | ||
| AHF | 11 (13.3) | 12 (17.1) | 10 (17.5) | 13 (13.5) | ||
| Second-line chemotherapy (n=125) | 0.006 | 0.038 | ||||
| Yes | 48 (80.0) | 37 (56.9) | 40 (78.4) | 45 (60.8) | ||
| No | 12 (20.0) | 28 (43.1) | 11 (21.6) | 29 (39.2) | ||
| Survival time (n=153) | ||||||
| Median PFS (range) | 13.0 (3.3–67.7) | 9.3 (1.2–64.9) | 0.006 | 11.0 (3.3–67.7) | 10.7 (1.2–60.0) | 0.315 |
| Median OS (range) | 31.0 (6.8–70.2) | 18.0 (6.0–64.9) | <0.01 | 31.0 (8.9–70.2) | 20.7 (6.0–68.7) | 0.015 |
Note: Data shown as n (%) unless indicated otherwise.
Abbreviations: NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LS, limited stage; ES, extensive stage; KPS, Karnofsky performance status; Hb, hemoglobin; ULN, upper limit of normal; LLN, lower limit of normal; Alb, albumin; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; sd, standard deviation; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RT, radiation therapy; CFR, conventional fraction radiotherapy; AHF, accelerated hyperfractionation; PFS, progression-free survival; OS, overall survival.